Philips Unveils AI-Powered CT and Helium-Free MRI Systems
Dual product launch aims to solidify leadership in high-end diagnostic imaging and accelerate growth amid company turnaround efforts.
Royal Philips (NYSE: PHG) today announced a significant expansion of its diagnostic imaging portfolio, unveiling two major platforms aimed at strengthening its competitive position: an AI-driven spectral CT scanner and the industry’s first helium-free 3.0T MRI system.
The Dutch health technology company introduced Verida, what it calls the world's first detector-based spectral CT system fully powered by artificial intelligence, designed to enhance diagnostic precision and workflow efficiency. The announcement was paired with the launch of the BlueSeal Horizon, a premium MRI platform that operates without liquid helium, a finite and costly resource critical for cooling traditional MRI magnets.
The dual announcements represent a concerted push by Philips to focus on high-end innovation as it seeks to move past recent operational challenges, including costly product recalls that have weighed on its performance. Shares of Philips traded modestly higher in morning trading, up 0.3% to $28.16, as investors digested the strategic implications of the new product pipeline.
AI at the Core of New CT Technology
The Verida CT system integrates AI across the entire imaging process, from image acquisition to reconstruction. According to a company statement, the platform can reduce energy consumption by up to 45% and process entire exams in under 30 seconds, more than twice as fast as previous systems. This efficiency is designed to allow for up to 270 exams per day, addressing the high-throughput needs of modern radiology departments.
“Combining the latest advances in our proven spectral CT technology with AI, our flagship Verida CT system is designed to set a new standard,” said Dan Xu, Business Leader of CT at Philips. Xu positioned the technology as a more practical and cost-effective alternative to emerging photon-counting CT systems, which he described as still being in the “research arena.” He noted that Philips' spectral CT “delivers comparable or better clinical outcomes... at significantly lower total cost of ownership.”
The company’s Diagnosis & Treatment segment, which includes these imaging systems, has shown resilience, reporting a 1% year-over-year comparable sales increase in its most recent quarter, with equipment order intake rising by 8%, according to its Q3 2025 earnings report.
A Breakthrough in MRI Operations
Alongside the new CT scanner, Philips highlighted its BlueSeal Horizon system, a significant development in MRI technology. Traditional MRI machines require thousands of liters of liquid helium to cool their superconducting magnets, representing a major operational expense and logistical challenge for hospitals. The BlueSeal magnet is fully sealed and operates with just seven liters of helium, which is then recycled, effectively creating a helium-free operational environment.
The innovation addresses a key pain point for healthcare providers and could provide Philips with a distinct competitive advantage in the premium MRI market. The push for more sustainable and economically efficient technology comes as healthcare systems worldwide face mounting financial pressures.
Strategic Shift Amid Turnaround
With a market capitalization of approximately $26.8 billion, Philips is navigating a critical juncture. The company has been working to restore investor confidence after being hampered by recalls, most notably related to its sleep apnea devices. These new product launches signal a renewed focus on its core strengths in diagnostic imaging, where it competes with giants like Siemens Healthineers and GE HealthCare.
Analysts have remained broadly positive on the company's prospects, with a consensus “Buy” rating and an average price target of $33.83, suggesting potential upside from the current stock price. The emphasis on AI and workflow efficiency is aligned with major industry trends, aiming to improve patient outcomes while reducing the burden on strained healthcare systems.
“The clinical benefits of Verida will fundamentally change my approach to cardiac imaging,” said Prof. Eliseo Vañó Galván, a cardiovascular radiologist at Hospital Nuestra Sra. Del Rosario in Madrid, Spain, who was cited in the company’s announcement. “We evaluated many systems... but chose Philips because it delivers the precision we need in a streamlined, easy-to-use platform.”
The Verida system is CE-marked and has a 510(k) application pending with the U.S. Food and Drug Administration, with availability in select markets expected to begin in 2026. The successful rollout of both the Verida CT and BlueSeal Horizon MRI will be a key catalyst for the company as it aims to solidify its market leadership and drive its next phase of growth.